GoAI
Get started
PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

PMVP

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.33

+$0.03 · +2.31%

Aug 21, 4:00 PM ET

Pre-market

$1.3348

+$0.0048 · +0.36%

Aug 24, 5:13 AM ET

PMVP company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

30

Expensive

Momentum

35

Weakening

Sentiment

62

Bullish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
David H. Mack
Listed since
Sep 25, 2020
Employees
54

Market position

Day range

Current $1.33

52-week range

Current $1.33

Open
$1.32
Previous close
$1.30
Volume
131.31K
0.39× average
Average volume
338.28K
Average daily volume
Market cap
70.93M USD
Beta
1.35
Market reference 1
50-day average
$1.2204
+8.98% above average
200-day average
$1.2714
+4.61% above average

Financials

Financial statements

Income trends

Operating income

−86.21M USD-0.89%

Net income

−77.74M USD-32.42%
Income trends across reported periods−55.01M USD−66.35M USD−77.7M USD−89.04M USDOperating income, FY2021: −58.29M USDOperating income, FY2022: −77.04M USDOperating income, FY2023: −80.13M USDOperating income, FY2024: −85.45M USDOperating income, FY2025: −86.21M USDNet income, FY2021: −57.85M USDNet income, FY2022: −73.32M USDNet income, FY2023: −68.96M USDNet income, FY2024: −58.71M USDNet income, FY2025: −77.74M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −58.29M USD. Operating income FY2022 −77.04M USD. Operating income FY2023 −80.13M USD. Operating income FY2024 −85.45M USD. Operating income FY2025 −86.21M USD. Net income FY2021 −57.85M USD. Net income FY2022 −73.32M USD. Net income FY2023 −68.96M USD. Net income FY2024 −58.71M USD. Net income FY2025 −77.74M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold—1.14M USD1.26M USD650K USD1.28M USD
Gross profit—−1.14M USD−1.26M USD−650K USD−1.28M USD
Research and development69.88M USD57.38M USD54.63M USD51.67M USD36.19M USD
Selling, general, and administrative16.33M USD26.92M USD24.25M USD24.72M USD20.83M USD
Operating expenses86.21M USD84.3M USD78.88M USD76.39M USD57.01M USD
Interest income6.34M USD10.66M USD11.17M USD3.63M USD449K USD
Depreciation and amortization133K USD1.14M USD1.26M USD650K USD1.28M USD
Operating income−86.21M USD−85.45M USD−80.13M USD−77.04M USD−58.29M USD
Net income−77.74M USD−58.71M USD−68.96M USD−73.32M USD−57.85M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy4100%
Hold00%
Sell00%
Strong sell00%

PMVP news

zacks.com

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read source
globenewswire.com

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule…

Read source
zacks.com

PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why

PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read source
zacks.com

PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could…

Read source

PMVP peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PMVP

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.65M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
502.12K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
211.43K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Avantis Total Equity Markets ETF 1 logoAvantis Total Equity Markets ETF 1AVTM
Market value
6.13K
Weight
—
AUM
795.5M USD
Expense ratio
0.23%
Price / 1D
$55.32020.00%

Continue in GoAI

Research PMVP

research.disclaimer